CompletedPhase 4

Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity

Italy50 participantsStarted 2011-04

Plain-language summary

The purpose of this study is to evaluate if high-dose (80mg/day) atorvastatin might exert an adjunctive anti-platelet effect compared to high-dose clopidogrel (150mg/day) in stable patients with high on-treatment reactivity according to a point-of-care platelet function assay.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Stable angina * candidates to drug eluting stent implantation * High on-treatment platelet reactivity according to a point-of-care platelet function test Exclusion Criteria: * chronic therapy with statins * inability to provide informed consent * intolerance to statins * acute or chronic liver failure or ALT \> 2 times ULN * known myopathy * CKD stage IV or dialysis treatment * pregnancy or breast-feeding * malignancy

What they're measuring

Change from baseline in on-treatment platelet reactivity at 7 and 30 days

Timeframe: pre-PCI, 7 days and 30 days

Trial details

NCT IDNCT01335048

SponsorOspedale Misericordia e Dolce

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-12

View on ClinicalTrials.gov More Stable Angina trials